HCR Wealth Advisors’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $757K | Buy |
5,887
+1,278
| +28% | +$150K | 0.07% | 135 |
|
|
2026
Q1 | $554K | Buy |
4,609
+53
| +1% | +$6.12K | 0.06% | 143 |
|
|
2025
Q4 | $480K | Buy |
4,556
+65
| +1% | +$6.1K | 0.05% | 153 |
|
|
2025
Q3 | $402K | Buy |
4,491
+484
| +12% | +$39.9K | 0.04% | 167 |
|
|
2025
Q2 | $317K | Sell |
4,007
-2,050
| -34% | -$163K | 0.04% | 179 |
|
|
2025
Q1 | $544K | Sell |
6,057
-13,639
| -69% | -$1.27M | 0.07% | 133 |
|
|
2024
Q4 | $1.96M | Sell |
19,696
-1,393
| -7% | -$144K | 0.25% | 65 |
|
|
2024
Q3 | $2.39M | Buy |
21,089
+78
| +0.4% | +$9.27K | 0.31% | 51 |
|
|
2024
Q2 | $2.6M | Buy |
21,011
+64
| +0.3% | +$8.24K | 0.37% | 42 |
|
|
2024
Q1 | $2.76M | Buy |
20,947
+966
| +5% | +$119K | 0.42% | 40 |
|
|
2023
Q4 | $2.18M | Buy |
19,981
+243
| +1% | +$25.2K | 0.34% | 50 |
|
|
2023
Q3 | $2.03M | Sell |
19,738
-1,027
| -5% | -$111K | 0.45% | 40 |
|
|
2023
Q2 | $2.4M | Sell |
20,765
-93
| -0.4% | -$10.6K | 0.44% | 38 |
|
|
2023
Q1 | $2.23M | Sell |
20,858
-1,100
| -5% | -$119K | 0.44% | 43 |
|
|
2022
Q4 | $2.45M | Sell |
21,958
-1,169
| -5% | -$119K | 0.51% | 38 |
|
|
2022
Q3 | $2.01M | Sell |
23,127
-70
| -0.3% | -$6.25K | 0.43% | 46 |
|
|
2022
Q2 | $2.13M | Sell |
23,197
-492
| -2% | -$43.6K | 0.43% | 51 |
|
|
2022
Q1 | $1.94M | Sell |
23,689
-308
| -1% | -$24.3K | 0.32% | 66 |
|
|
2021
Q4 | $1.84M | Sell |
23,997
-188
| -0.8% | -$15K | 0.29% | 75 |
|
|
2021
Q3 | $1.82M | Sell |
24,185
-234
| -1% | -$17.8K | 0.3% | 75 |
|
|
2021
Q2 | $1.9M | Sell |
24,419
-2,988
| -11% | -$222K | 0.33% | 70 |
|
|
2021
Q1 | $2.02M | Sell |
27,407
-3,844
| -12% | -$284K | 0.4% | 56 |
|
|
2020
Q4 | $2.44M | Buy |
31,251
+1,037
| +3% | +$79.3K | 0.51% | 32 |
|
|
2020
Q3 | $2.38M | Buy |
30,214
+1,226
| +4% | +$96K | 0.54% | 33 |
|
|
2020
Q2 | $2.16M | Sell |
28,988
-146
| -0.5% | -$11K | 0.51% | 28 |
|
|
2020
Q1 | $2.14M | Buy |
29,134
+102
| +0.4% | +$8.02K | 0.61% | 27 |
|
|
2019
Q4 | $2.52M | Buy |
29,032
+4,189
| +17% | +$344K | 0.61% | 30 |
|
|
2019
Q3 | $1.99M | Sell |
24,843
-611
| -2% | -$49K | 0.66% | 33 |
|
|
2019
Q2 | $2.04M | Buy |
25,454
+320
| +1% | +$24.5K | 0.58% | 33 |
|
|
2019
Q1 | $1.99M | Buy |
25,134
+2,061
| +9% | +$154K | 0.57% | 37 |
|
|
2018
Q4 | $1.68M | Buy |
23,073
+293
| +1% | +$20.7K | 0.54% | 39 |
|
|
2018
Q3 | $1.57M | Buy |
22,780
+209
| +0.9% | +$13.3K | 0.51% | 48 |
|
|
2018
Q2 | $1.31M | Sell |
22,571
-864
| -4% | -$48.7K | 0.43% | 53 |
|
|
2018
Q1 | $1.22M | Buy |
23,435
+461
| +2% | +$24.9K | 0.42% | 57 |
|
|
2017
Q4 | $1.23M | Buy |
22,974
+10,844
| +89% | +$601K | 0.43% | 53 |
|
|
2017
Q3 | $741K | Buy |
12,130
+88
| +0.7% | +$5.33K | 0.31% | 80 |
|
|
2017
Q2 | $736K | Sell |
12,042
-73
| -0.6% | -$4.44K | 0.36% | 66 |
|
|
2017
Q1 | $735K | Buy |
12,115
+2,478
| +26% | +$150K | 0.38% | 68 |
|
|
2016
Q4 | $541K | Buy |
+9,637
| New | +$564K | 0.29% | 80 |
|
Other funds holding MRK
ECSS
HCR Wealth Advisors's MRK Position: Q2 2026 in Review
HCR Wealth Advisors increased its Merck (MRK) stake by 28% in Q2 2026, buying an estimated $150K and bringing the position to 5,887 shares worth $757K. The position accounts for 0.07% of the portfolio, ranked #135.
HCR Wealth Advisors first reported a position in MRK in Q4 2016 and has held it in 39 quarters since. The position peaked at $2.76M in Q1 2024. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.
- HCR Wealth Advisors held 5,887 shares of Merck worth $757K as of Q2 2026.
- HCR Wealth Advisors bought 1,278 Merck shares in Q2 2026, an estimated $150K.
- Merck made up 0.07% of HCR Wealth Advisors's portfolio in Q2 2026, its #135 holding.
- HCR Wealth Advisors first reported a position in Merck in Q4 2016 and has held it in 39 quarters since.
- HCR Wealth Advisors's Merck position peaked at $2.76M in Q1 2024.
- 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.
Based on HCR Wealth Advisors's 13F filing for Q2 2026, filed 13 Jul 2026.